Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

04/04/2024 Eastern Time in USA The Dow Jones Industrial Average(DJI.US) dropped by 1.35%, closing at 38596.98 points; the NASDAQ(IXIC.US) dropped by 1.4%, closing at 16049.08 points; the S&P 500 index(SPX.US) dropped by 1.23%, closing at 5147.21 points. 

Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

1、CANDEL THERAPEUTICS, INC.: Overnight gain 281.0%, Stock Boost Linked to Advancements in Glioma Treatment and Strategic Collaborations

Candel Therapeutics, Inc. (hereinafter referred to as "Candel"), established in June 2003 and headquartered in Delaware, is a late-stage biopharmaceutical company specializing in the development of oncolytic virus immunotherapies designed to benefit cancer patients. The company's engineered viruses work by inducing immunogenic cell death in cancer cells and creating a pro-inflammatory microenvironment in the injection site, leading to the release of tumor neoantigens. With a solid foundation in viral immunotherapy knowledge and extensive clinical expertise, Candel targets a broad spectrum of cancer indications.

Shares of CANDEL THERAPEUTICS, INC.(CADL.US) have witnessed a notable ascent, which analysts believe may be correlated with the company’s string of positive developments in the treatment of high-grade gliomas. 

The promising clinical trial results of its candidate drug, CAN-3110, have shown a doubling in the expected median overall survival in Phase 1b trials for recurrent high-grade gliomas. This significant milestone was further bolstered by the Fast Track designation granted by the U.S. Food and Drug Administration (FDA), offering an expedited pathway for the drug's development. 

Furthermore, Candel Therapeutics’ collaboration with Batavia Biosciences has streamlined the drug development and manufacturing process, enhancing operational efficiency. Encouraging data from the company’s mid-stage clinical trials in the treatment of non-metastatic pancreatic cancer have also fortified investor confidence in the potential of the company’s pipeline.

The robust financial position of Candel Therapeutics, along with its projected cash runway, provides a solid foundation for its ongoing research and development endeavors. These collective factors are likely contributing to an optimistic outlook among investors regarding the company’s future growth prospects, thereby propelling the upward trajectory of CADL’s stock price.

2、Allurion Technologies, Inc. Common Stock: Overnight gain 78.0%, Rise Attributed to Positive Analyst Coverage, AI-Driven Product Launches, and Industry Exposure.

In recent financial news, Allurion Technologies, Inc. Common Stock(ALUR.US) has experienced a notable surge in share price, which can be attributed to a confluence of favorable developments. Initiated coverage by Chardan Capital analyst Keay Nakae has bestowed a bullish 'buy' rating and an optimistic price target on the stock, instilling increased confidence among investors in Allurion Technologies' market prospects.

Further bolstering investor sentiment is the company's announcement of the commercial availability of its Virtual Care Suite (VCS) in the United States. This AI-driven weight management suite, which integrates remote patient monitoring and medical collaboration tools, signifies an innovative leap in the telehealth sector for Allurion Technologies and hints at potential business expansion.

Additional momentum comes from the company's launch of new products and technologies, such as the Coach Iris AI weight loss coach and the forthcoming Allurion Insights, demonstrating Allurion Technologies' commitment to continuous investment in product innovation and technological advancement.

Lastly, the company's strategic plan to showcase its products at prominent industry conferences is expected to enhance brand visibility and facilitate engagement with prospective clients. Collectively, these factors are contributing to the upward trajectory of Allurion Technologies' stock price.

3、MacroGenics, Inc.: Overnight gain 30.1%, Stock Rises on Positive Mid-Stage Prostate Cancer Drug Data and Analyst Optimism.

MacroGenics, Inc., a biopharmaceutical firm established on August 14, 2000, in Delaware, United States, focuses on the development of innovative therapies based on monoclonal antibodies aimed at treating cancer and autoimmune diseases. Leveraging its sophisticated antibody technology platform, the company is advancing drug candidates with the goal of enhancing the efficacy of monoclonal antibodies and their derivatives. With a deep understanding of disease biology and immunological mechanisms, MacroGenics has identified potential candidates that may address specific disease challenges unmet by current treatment modalities. The company is dedicated to the development of molecules targeting novel oncological markers and to improving the potency of existing therapeutics.

In the latest financial news, MacroGenics, Inc.(MGNX.US) has experienced a notable surge in its stock price. This upward momentum is believed to be driven by several catalysts. Foremost among these is the company's announcement of encouraging mid-stage clinical data for its antibody-drug conjugate, vobramitamab duocarmazine, in the treatment of prostate cancer. 

The reported good safety and tolerability profiles have bolstered confidence in the drug's potential for treating metastatic castration-resistant prostate cancer (mCRPC).

Furthermore, optimistic ratings from analysts have provided additional support to the stock's ascent. Expectations are set for MacroGenics to release more research data in the near future, which will delve deeper into the therapeutic efficacy and market potential of vobramitamab duocarmazine. These factors collectively contribute to the market's positive outlook on the future prospects of MacroGenics, Inc. (MGNX).

4、Tevogen Bio Holdings Inc. - Common Stock: Overnight gain 29.8%, Rises on Strong Performance, Business Growth, and Sector Optimism

In recent trading sessions, shares of Tevogen Bio Holdings Inc. - Common Stock(TVGN.US) have experienced a noteworthy surge. This uptick may be attributed to the company's release of a financial performance report that exceeded market expectations or demonstrated positive signs of business growth. 

Additionally, the stock may be garnering increased investor attention due to significant positive developments, such as breakthroughs in new product offerings, the signing of substantial contracts, or innovative achievements within the realm of scientific research.

Furthermore, the overall market trends in the biotech sector or prevailing optimistic sentiment within the industry could be contributing factors to the upward momentum in Tevogen Bio Holdings' stock price. 

In the event that the company secures regulatory approval for new pharmaceuticals or is granted patents, such milestones could significantly bolster its competitive edge in the market, subsequently attracting investor interest in purchasing shares.Rumors or announcements of mergers and acquisitions activities could also play a role in the stock's ascent. 

In conclusion, this price fluctuation is the result of various factors, and investors are advised to stay closely attuned to company developments and market dynamics.

5、Nektar Therapeutics: Overnight gain 26.9%, Stock Surge Tied to Clinical Trials, Partnerships, and Regulatory Milestones

Since its inception in California in 1990 and subsequent re-incorporation in Delaware in 1998, Nektar Therapeutics has established itself as a clinical-stage biopharmaceutical company with a laser focus on the development of novel drug candidates across multiple therapeutic areas, including oncology, pain, anti-infectives, and immunology. Leveraging its proprietary PEGylation technology and sophisticated polymer conjugate technology platforms, Nektar is advancing a pipeline of both small-molecule and biologic drug candidates.The company's research and development efforts are geared toward modifying pharmacokinetic genes using its exclusive technologies to create new molecular entities with enhanced therapeutic profiles. Nektar Therapeutics' revenue streams are primarily derived from strategic partnership agreements, encompassing contract research payments, milestone payments contingent upon clinical and regulatory achievements, royalties, and production revenues.

It is noteworthy that shares of Nektar Therapeutics(NKTR.US) have recently experienced a notable uptick, a trend that could be associated with several key drivers. 

Firstly, the company may have announced positive results from clinical trials, particularly for its pipeline candidates in pivotal stages, which typically bolster market confidence in their commercialization prospects. 

Secondly, advancements or new partnerships with other pharmaceutical or biotech entities may have occurred for Nektar, with milestone achievements in these collaborations often acting as catalysts for share price appreciation. 

Furthermore, if the company’s drug candidates have received regulatory approval or have been subject to favorable regulatory designations that could expedite development, this would also positively influence the stock performance.

Additionally, the release of financial results that surpass market expectations, such as unexpected increases in revenue and profits, usually draw investor interest. Concurrently, overarching trends in the biopharmaceutical sector, such as an uptick in merger and acquisition activities, could lead to speculation of NKTR as a potential acquisition target, thereby driving up its share price. 

The successful filing or approval of key technological patents or drug patents may also contribute to the upward movement of the stock.

Moreover, shifts in market sentiment and optimistic investor outlook on the company’s future growth prospects could directly result in stock price fluctuations. Taking into account these various factors, the ascension in NKTR’s stock price might be the culmination of a confluence of positive market dynamics.

6、Destiny Tech100 Inc.: Overnight gain 24.1%, Stock Surge Driven by Multiple Positive Factors and Market Optimism

Destiny Tech100 Inc.(DXYZ.US) has recently garnered attention for its impressive stock performance, with a notable upward trend that may be attributed to a confluence of factors. Among these, the company may have reported financial results that exceeded expectations, indicative of enhanced profitability and competitive strength in the marketplace. 

Moreover, should Destiny Tech100 Inc. (DXYZ) have introduced innovative products or services, or announced significant technological advancements, such developments are likely to ignite optimistic market expectations for the company’s future growth potential. A marked increase in industry demand or an expansion of the company’s market share could also be key drivers propelling the stock price upward. 

Similarly, announcements of significant partnerships or acquisition deals are often interpreted by the market as positive indicators of the company’s strategic positioning and long-term prospects. Additionally, a buoyant investment sentiment in the overall market or within a specific sector, along with improvements in the macroeconomic climate such as interest rate adjustments or shifts in monetary policy, could all exert a positive influence on DXYZ’s share value. 

Lastly, the buying actions of large institutional investors cannot be overlooked, as such behavior can directly impact stock price movements. However, a comprehensive understanding of the precise reasons behind the stock’s rise necessitates an integrated assessment that includes specific company announcements, market news, analyst reports, and industry trends.

7、Simulations Plus: Overnight gain 23.6%, Stock Rises Amid Positive Performance, Analysts' Ratings, and Optimistic Growth Outlook

Simulations Plus, Inc. (hereinafter referred to as "the Company") was established in the state of California on July 17, 1996, and has since been dedicated to the development of simulation and modeling software for the pharmaceutical discovery and development sectors. The company's software incorporates artificial intelligence and machine learning technologies to predict molecular properties. In addition to its software offerings, Simulations Plus provides consulting services that span from early-stage drug discovery through preclinical and clinical trial phases, including assistance with regulatory submission documents. The company's software and consulting services are extensively utilized by a global clientele across the pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries, as well as by academic and regulatory bodies, to support industry research.

It is noteworthy that Simulations Plus(SLP.US) has recently experienced a significant surge in its stock price, which may be attributed to a confluence of positive factors. To begin with, the company reported quarterly earnings that exceeded analysts' expectations, demonstrating robust financial growth momentum, and in turn, bolstering market confidence in the company's future outlook. 

Additionally, the company achieved a notable year-over-year increase in sales revenue, further underscoring a trend of business expansion and steady revenue growth.

Analysts have continued to bestow a 'buy' rating on Simulations Plus, bolstering investor confidence. Crucially, Simulations Plus issued an optimistic growth guidance for the fiscal year, showcasing management's confidence in the company's future development. 

Moreover, the enhancement of the company's ESG (Environmental, Social, and Governance) rating reflects positive strides in sustainable development, drawing the attention of investors with a focus on responsible investing.Lastly, as a high-tech enterprise specializing in drug discovery and development, Simulations Plus benefits from the robust demand for advanced technologies within the industry. Collectively, these factors have contributed to the company's upward trajectory in stock valuation.

8、STAAR Surgical Company: Overnight gain 16.5%, Stock Rises on Strong Sales, Optimistic Outlook, and Market Confidence.

STAAR Surgical Company, a global leader in the refractive surgery sector, is dedicated to the design, development, manufacture, and sale of implantable intraocular lenses (IOLs). The company's lenses are extensively utilized in the treatment of cataracts and various other ophthalmic surgeries, featuring a foldable design that allows surgeons to perform minimally invasive implantation through small incisions. STAAR Surgical's suite of refractive solutions includes Implantable Collamer Lenses (ICL) and laser procedures such as LASIK, which are designed to correct common visual impairments such as myopia, hyperopia, and astigmatism. Originally established in California in 1982, the company underwent a re-incorporation in Delaware in 1986.

It is noteworthy that STAAR Surgical Company(STAA.US) has recently seen a significant surge in its stock price, bolstered by a host of positive factors. Specializing in the development of ophthalmic surgical products, particularly Implantable Collamer Lenses (ICL), the company commands substantial brand influence within this niche market. 

STAAR Surgical's preliminary net sales have exceeded expectations, showcasing robust sales performance and directly bolstering investor confidence. The surge in ICL sales within the United States, reaching record levels, underscores the product's growth momentum in the core market. 

Furthermore, the company's optimistic sales forecast for the fiscal year 2024, coupled with management's positive outlook, indicates STAAR Surgical's sustained confidence in its business development and market prospects. The company's solid financial improvement and guidance in line with analyst expectations have also been key drivers of the stock's ascent. In summary, STAAR Surgical's market performance, anticipated growth in earnings, and strong financial foundation have collectively contributed to the appreciation of its share price.

9、ZETA GLOBAL HOLDINGS CORP.: Overnight gain 13.3%, Rising Stock Influenced by Analyst Optimism and Strong Revenue Growth

Zeta Global Holdings Corp. (hereinafter referred to as "Zeta"), established on May 9, 2012, in accordance with Delaware state regulations, is a leading entity in providing omnichannel data-driven cloud services. Zeta is dedicated to delivering consumer intelligence and marketing automation solutions to businesses, enabling clients to execute personalized marketing campaigns across various addressable channels including email, social media, websites, chat, Connected TV (CTV), and video. The company's software is designed to help clients accurately target, connect with, and engage consumers.

ZETA GLOBAL HOLDINGS CORP.(ZETA.US) has seen a notable uptick in its share price recently, potentially buoyed by a confluence of positive factors. Analysts have been shining a spotlight on the company, with a slew of optimistic future performance projections. Clark Wright from DA Davidson initiated coverage on the firm, bestowing a 'Buy' rating and setting an ambitious price target. 

Similarly, analysts from prestigious financial institutions such as Morgan Stanley and Barclays have also upgraded their ratings and price targets, reflecting a market confidence in the company's prospective earnings growth.

Despite earnings per share falling short of expectations, the company's financial report revealed revenue figures that surpassed market forecasts, indicating robust business growth momentum. This outperformance in earnings typically bolsters investor expectations about the company's long-term growth potential. Increased market engagement is also a critical factor contributing to the rise in stock price.

Morgan Stanley analyst Elizabeth Porter highlighted that as market recognition of Zeta Global Holdings grows, the company has seen an uptick in its participation in RFPs (Requests for Proposals), transaction success rates, and customer acquisition, signaling an enhancement in its competitive market stance.Lastly, with the gradual phase-out of third-party cookies, there may be a rising demand for Zeta Global Holdings' data-driven marketing automation software, leading to heightened market interest in the company's services. 

The aggregate effect of these factors on investor sentiment is likely a principal driver behind the recent appreciation in Zeta Global Holdings' share value.

10、Aldeyra Therapeutics, Inc.: Overnight gain 12.9%, Stock Rises on Drug Application Confidence, Strategic Alliances, and Positive Financial Outlook

Aldeyra Therapeutics, Inc., founded on August 13, 2004, is a Delaware-based biotechnology firm engaged in the discovery and development of novel therapeutics for the treatment of immune-mediated diseases, inflammatory disorders, rare conditions, and diseases associated with free aldehyde toxicity. The company's lead product candidate, reproxalap, is primarily focused on addressing dry eye disease and other ocular inflammations. In addition, Aldeyra is actively pursuing the development of treatments for autoimmune diseases, post-transplant lymphoproliferative disorder, retinal inflammation, metabolic disorders, and cancer. To date, none of the company's product candidates have received regulatory approval for commercialization in the United States or any other market.

In a noteworthy development, shares of Aldeyra Therapeutics, Inc.(ALDX.US) have recently exhibited an upward trend, buoyed by a confluence of key factors. Firstly, the company announced its intention to resubmit the New Drug Application (NDA) for its dry eye disease candidate, reproxalap, in the latter half of the year, signaling confidence in securing regulatory approval. 

Additionally, the collaboration with AbbVie has lent substantial support to the drug's development, bolstering market confidence. Positive analyst ratings and established price targets have further fueled the stock's ascent. Moreover, the firm's robust financial health, coupled with insider stock purchases by executives, reflect an optimistic outlook for the company's future trajectory. 

Collectively, Aldeyra Therapeutics' progress in drug development, strategic partnership alliances, and financial stability are pivotal factors driving the appreciation in its share price.

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.